Abstract Body

Rilpivirine (RPV) is mainly metabolised by cytochrome P450 (CYP) enzymes but less is known about the importance of transporters in its disposition. Many enzymes and transporters are transcriptionally regulated by the pregnane-X-receptor (PXR; NR1I2). In this study, we sought to determine associations between genetic variants within the genes coding for these proteins and RPV plasma concentrations.

Blood samples were collected 12 hours post dose (C[sub]12[/sub]) from 150 patients receiving RPV-containing regimens recruited in Turin (Italy) and London (UK). Plasma concentrations of RPV were analysed by validated LC-MS/MS methods. Genotyping was conducted by real-time PCR-based allelic discrimination using standard methods for the following polymorphisms: [i]CYP3A4*22[/i] (rs35599367), [i]CYP2C19*2[/i] (rs4244285), [i]CYP2C19*17[/i] (rs12248560), [i]NR1I2[/i] (rs2472677), [i]SLC22A1[/i] (rs628031, rs72552763, rs622342 and rs683369), [i]SLCO2B1[/i] (rs1077858, rs12422149, rs35199625, rs2712807 and rs2851069). Data were log transformed, and univariate and multivariate linear regression was used to investigate associations. All data are given as mean with standard deviation.

Patients were 42.7 (11.1) years old, with height 173.5 (8.3) cm, weight 72.3 (12.4) kg and C12171.4 (80.9) ng. mL-1. 86% were male, 98% were white, 74.7% received emtricitabine with tenofovir disoproxil fumarate (FTC/TDF), 23.3% received ritonavir-boosted darunavir (DRV/r), and 2% received abacavir with lamivudine (ABC/3TC). All SNPs were in Hardy-Weinberg equilibrium and carrier/non-carrier analyses were applied in regression analyses. In univariate linear regression, differences in C12 were associated with height (P= 0.01) and CYP3A4*22 (P= 0.01). Differences in C12 were also seen between patients receiving different backbone therapies. CYP3A4*22 (P= 0.02, β= -0.17), and concomitant drugs (P= 0.02, β= -0.09) remained significant in multivariate linear regression (see table).

These results indicate that CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with RPV pharmacokinetics but further studies are required to confirm this association. While the impact of CYP3A4*22 on C12 was relatively minor, a more marked effect would be expected after administration of the RPV long-acting depot and this warrants further investigation.